Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sight Sciences (SGHT) Gains from Sales and Divestitures (2022 - 2025)

Sight Sciences (SGHT) has 4 years of Gains from Sales and Divestitures data on record, last reported at $1.7 million in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 33.02% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, up 33.02%, while the annual FY2025 figure was $1.7 million, 33.02% up from the prior year.
  • Gains from Sales and Divestitures reached $1.7 million in Q4 2025 per SGHT's latest filing, up from $1.2 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.7 million in Q4 2025 and bottomed at $11028.0 in Q4 2022.
  • Average Gains from Sales and Divestitures over 4 years is $817506.5, with a median of $878707.0 recorded in 2024.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 2109.51% in 2023, then soared 33.02% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $11028.0 in 2022, then surged by 2109.51% to $243665.0 in 2023, then skyrocketed by 411.64% to $1.2 million in 2024, then soared by 33.02% to $1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $1.7 million in Q4 2025, $1.2 million in Q3 2025, and $874208.0 in Q2 2025.